Cell-Penetrating Peptides: From Basic Research to Clinics

Trends in Pharmacological Sciences

Volumn 38, Issue 4, 2017, Pages 406-424

  Guidotti, Giulia ^a   Brambilla, Liliana ^a   Rossi, Daniela ^a  

^a IRCCS   (Italy)

Author keywords

cell penetrating peptides; clinical trials; internalization; therapy

Indexed keywords

AMPHIPATHIC CELL PENETRATING PEPTIDE; CATALASE; CATIONIC CELL PENETRATING PEPTIDE; CELL PENETRATING PEPTIDE; COPPER ZINC SUPEROXIDE DISMUTASE; DRUG CARRIER; FIRTECAN; HYDROPHOBIC CELL PENETRATING PEPTIDE; I KAPPA B KINASE GAMMA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MORPHOLINO OLIGONUCLEOTIDE; PEPTIDE NUCLEIC ACID; PROTEIN BCL 2; PROTEIN BCL XL; REACTIVE OXYGEN METABOLITE; STRESS ACTIVATED PROTEIN KINASE; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG;

ACUTE HEART INFARCTION; ALPHA HELIX; ALZHEIMER DISEASE; AMINO ACID SEQUENCE; AMYOTROPHIC LATERAL SCLEROSIS; BETA SHEET; BLOOD BRAIN BARRIER; BRAIN ISCHEMIA; CATARACT EXTRACTION; CELL MEMBRANE PERMEABILITY; CLASSIFICATION; COCHLEA INJURY; CONJUGATION; DRUG TRANSPORT; DUCHENNE MUSCULAR DYSTROPHY; ENDOCYTOSIS; GENETIC TRANSFECTION; HYDROPHILICITY; HYDROPHOBICITY; HYPOXIC ISCHEMIC ENCEPHALOPATHY; INTERNALIZATION; MEMBRANE TRANSDUCTION; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OXIDATIVE STRESS; PERCEPTION DEAFNESS; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PSORIASIS; REVIEW; STRUCTURE ACTIVITY RELATION; ANIMAL; HUMAN; METABOLISM; PHYSIOLOGY;

ANIMALS; CELL-PENETRATING PEPTIDES; ENDOCYTOSIS; HUMANS; NF-KAPPA B; REACTIVE OXYGEN SPECIES;

EID: 85012941083     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2017.01.003     Document Type: Review

References (131)

1. 1 Langel, U., Cell-Penetrating Peptides. Methods and Protocols. 2nd edn, 2015, Humana Press.
2. 2 Frankel, A.D., Pabo, C.O., Cellular uptake of the tat protein from human immunodeficiency virus. Cell 55 (1988), 1189–1193.
3. 3 Green, M., Loewenstein, P.M., Autonomous functional domains of chemically synthesized human immunodeficiency virus tat trans-activator protein. Cell 55 (1988), 1179–1188.
4. 4 Joliot, A., et al. Antennapedia homeobox peptide regulates neural morphogenesis. Proc. Natl. Acad. Sci. U. S. A. 88 (1991), 1864–1868.
5. 5 Derossi, D., et al. The third helix of the Antennapedia homeodomain translocates through biological membranes. J. Biol. Chem. 269 (1994), 10444–10450.
6. 6 Vivès, E., et al. A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus. J. Biol. Chem. 272 (1997), 16010–16017.
7. 7 Park, J., et al. Mutational analysis of a human immunodeficiency virus type 1 Tat protein transduction domain which is required for delivery of an exogenous protein into mammalian cells. J. Gen. Virol. 83 (2002), 1173–1181.
8. 8 Elliott, G., O'Hare, P., Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 88 (1997), 223–233.
9. 9 Pooga, M., et al. Cell penetrating PNA constructs regulate galanin receptor levels and modify pain transmission in vivo. Nat. Biotechnol. 16 (1998), 857–861.
10. 10 Futaki, S., et al. Arginine-rich peptides. An abundant source of membrane-permeable peptides having potential as carriers for intracellular protein delivery. J. Biol. Chem. 276 (2001), 5836–5840.
11. 11 Oehlke, J., et al. Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically. Biochim. Biophys. Acta 1414 (1998), 127–139.
12. 12 Ramsey, J.D., Flynn, N.H., Cell-penetrating peptides transport therapeutics into cells. Pharmacol. Ther. 154 (2015), 78–86.
13. 13 Raucher, D., Ryu, J.S., Cell-penetrating peptides: strategies for anticancer treatment. Trends Mol. Med. 21 (2015), 560–570.
14. 14 Bechara, C., Sagan, S., Cell-penetrating peptides: 20 years later, where do we stand?. FEBS Lett. 587 (2013), 1693–1702.
15. 15 Heitz, F., et al. Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics. Br. J. Pharmacol. 157 (2009), 195–206.
16. 16 Regberg, J., et al. Applications of cell-penetrating peptides for tumor targeting and future cancer therapies. Pharmaceuticals (Basel) 5 (2012), 991–1007.
17. 17 Copolovici, D.M., et al. Cell-penetrating peptides: design, synthesis, and applications. ACS Nano 8 (2014), 1972–1994.
18. 18 Vasconcelos, L., et al. Therapeutic potential of cell-penetrating peptides. Ther. Deliv. 4 (2013), 573–591.
19. 19 Bates, E., et al. Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction. Circulation 117 (2008), 886–896.
20. 20 Brandt, F., et al. Efficacy and safety evaluation of a novel botulinum toxin topical gel for the treatment of moderate to severe lateral canthal lines. Dermatol. Surg. 36:Suppl. 4 (2010), 2111–2118.
21. 21 Cao, G., et al. In vivo delivery of a Bcl-xL fusion protein containing the TAT protein transduction domain protects against ischemic brain injury and neuronal apoptosis. J. Neurosci. 22 (2002), 5423–5431.
22. 22 Cirak, S., et al. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-escalation study. Lancet 378 (2011), 595–605.
23. 23 Cousins, M.J., et al. The safety and efficacy of KAI-1678 – an inhibitor of epsilon protein kinase C (εPKC) – versus lidocaine and placebo for the treatment of postherpetic neuralgia: a crossover study design. Pain Med. 14 (2013), 533–540.
24. 24 Delfin, D.A., et al. Improvement of cardiac contractile function by peptide-based inhibition of NF-κB in the utrophin/dystrophin-deficient murine model of muscular dystrophy. J. Transl. Med., 9, 2011, 68.
25. 25 Deloche, C., et al. XG-102 administered to healthy male volunteers as a single intravenous infusion: a randomized, double-blind, placebo-controlled, dose-escalating study. Pharmacol. Res. Perspect., 2, 2014, e00020.
26. 26 Kinali, M., et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 8 (2009), 918–928.
27. 27 Lopes, L.B., et al. Cell permeant peptide analogues of the small heat shock protein, HSP20, reduce TGF-β1-induced CTGF expression in keloid fibroblasts. J. Invest. Dermatol. 129 (2009), 590–598.
28. L rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals. Hum. Mol. Genet. 21 (2012), 826–840.
29. 29 Peterson, J.M., et al. Peptide-based inhibition of NF-κB rescues diaphragm muscle contractile dysfunction in a murine model of Duchenne muscular dystrophy. Mol. Med. 17 (2011), 508–515.
30. 30 Sclip, A., et al. c-Jun N-terminal kinase has a key role in Alzheimer disease synaptic dysfunction in vivo. Cell Death Dis., 5, 2014, e1019.
31. 31 Warso, M.A., et al. A first-in-class, first-in-human, Phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br. J. Cancer 108 (2013), 1061–1070.
32. 32 Yang, D., et al. Intranasal delivery of cell-penetrating anti-NF-κB peptides (Tat–NBD) alleviates infection-sensitized hypoxic–ischemic brain injury. Exp. Neurol. 247 (2013), 447–455.
33. 33 El Zaoui, I., et al. Subconjunctival injection of XG-102, a c-Jun N-terminal kinase inhibitor peptide, in the treatment of endotoxin-induced uveitis in rats. J. Ocul. Pharmacol. Ther. 31 (2015), 17–24.
34. 34 Hosseini, A., et al. Efficacy of a phosphorodiamidate morpholino oligomer antisense compound in the inhibition of corneal transplant rejection in a rat cornea transplant model. J. Ocul. Pharmacol. Ther. 28 (2012), 194–201.
35. 35 Meyer-Losic, F., et al. DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies. Clin. Cancer Res. 14 (2008), 2145–2153.
36. 36 Wender, P.A., et al. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U. S. A.​ 97 (2000), 13003–13008.
37. 37 De Coupade, C., et al. Novel human-derived cell-penetrating peptides for specific subcellular delivery of therapeutic biomolecules. Biochem. J. 390 (2005), 407–418.
38. 38 Tünnemann, G., et al. Live-cell analysis of cell penetration ability and toxicity of oligo-arginines. J. Pept. Sci. 14 (2008), 469–476.
39. 39 Rothbard, J.B., et al. Role of membrane potential and hydrogen bonding in the mechanism of translocation of guanidinium-rich peptides into cells. J. Am. Chem. Soc. 126 (2004), 9506–9507.
40. 40 Koren, E., Torchilin, V.P., Cell-penetrating peptides: breaking through to the other side. Trends Mol. Med. 18 (2012), 385–393.
41. 41 Zaro, J.L., Shen, W.-C., Cationic and amphipathic cell-penetrating peptides (CPPs): their structures and in vivo studies in drug delivery. Front. Chem. Sci. Eng. 9 (2015), 407–427.
42. 42 Milletti, F., Cell-penetrating peptides: classes, origin, and current landscape. Drug Discov. Today 17 (2012), 850–860.
43. 43 Morris, M.C., et al. Cell-penetrating peptides: from molecular mechanisms to therapeutics. Biol. Cell 100 (2008), 201–217.
44. 44 Elmquist, A., et al. Structure–activity relationship study of the cell-penetrating peptide pVEC. Biochim. Biophys. Acta 1758 (2006), 721–729.
45. 45 Johansson, H.J., et al. Characterization of a novel cytotoxic cell-penetrating peptide derived from p14ARF protein. Mol. Ther. 16 (2008), 115–123.
46. 46 Magzoub, M., et al. N-terminal peptides from unprocessed prion proteins enter cells by macropinocytosis. Biochem. Biophys. Res. Commun. 348 (2006), 379–385.
47. 47 Taylor, B.N., et al. Noncationic peptides obtained from azurin preferentially enter cancer cells. Cancer Res. 69 (2009), 537–546.
48. 48 Yamada, T., et al. p28, a first in class peptide inhibitor of cop1 binding to p53. Br. J. Cancer 108 (2013), 2495–2504.
49. 49 Oehlke, J., et al. Extensive cellular uptake into endothelial cells of an amphipathic beta-sheet forming peptide. FEBS Lett. 415 (1997), 196–199.
50. 50 Sadler, K., et al. Translocating proline-rich peptides from the antimicrobial peptide bactenecin 7. Biochemistry 41 (2002), 14150–14157.
51. 51 Pujals, S., Giralt, E., Proline-rich, amphipathic cell-penetrating peptides. Adv. Drug Deliv. Rev. 60 (2008), 473–484.
52. 52 Marks, J.R., et al. Spontaneous membrane-translocating peptides by orthogonal high-throughput screening. J. Am. Chem. Soc. 133 (2011), 8995–9004.
53. 53 Rhee, M., Davis, P., Mechanism of uptake of C105Y, a novel cell-penetrating peptide. J. Biol. Chem. 281 (2006), 1233–1240.
54. 54 Gao, C., A cell-penetrating peptide from a novel pVII–pIX phage-displayed random peptide library. Bioorg. Med. Chem. 10 (2002), 4057–4065.
55. 55 Schafmeister, C.E., An all-hydrocarbon cross-linking system for enhancing the helicity and metabolic stability of peptides. J. Am. Chem. Soc. 122 (2000), 5891–5892.
56. 56 Ochocki, J.D., et al. Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis. Methods Mol. Biol. 1088 (2014), 213–223.
57. 57 Covic, L., et al. Activation and inhibition of G protein-coupled receptors by cell-penetrating membrane-tethered peptides. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 643–648.
58. 58 O'Callaghan, K., et al. Turning receptors on and off with intracellular pepducins: new insights into G-protein-coupled receptor drug development. J. Biol. Chem. 287 (2012), 12787–12796.
59. 59 Mueller, J., et al. Comparison of cellular uptake using 22 CPPs in 4 different cell lines. Bioconjug. Chem. 19 (2008), 2363–2374.
60. + leukaemia cells. Biochem. J. 403 (2007), 335–342.
61. 61 Kosuge, M., et al. Cellular internalization and distribution of arginine-rich peptides as a function of extracellular peptide concentration, serum, and plasma membrane associated proteoglycans. Bioconjug. Chem. 19 (2008), 656–664.
62. 62 Lundberg, M., et al. Cell surface adherence and endocytosis of protein transduction domains. Mol. Ther. 8 (2003), 143–150.
63. 63 Hirose, H., et al. Transient focal membrane deformation induced by arginine-rich peptides leads to their direct penetration into cells. Mol. Ther. 20 (2012), 984–993.
64. 64 Palm-Apergi, C., et al. Do cell-penetrating peptides actually “penetrate” cellular membranes?. Mol. Ther. 20 (2012), 695–697.
65. 65 Herce, H.D., Garcia, A.E., Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc. Natl. Acad. Sci. U. S. A.​ 104 (2007), 20805–20810.
66. 66 Herce, H.D., et al. Arginine-rich peptides destabilize the plasma membrane, consistent with a pore formation translocation mechanism of cell-penetrating peptides. Biophys. J. 97 (2009), 1917–1925.
67. 67 Herce, H.D., et al. Fundamental molecular mechanism for the cellular uptake of guanidinium-rich molecules. J. Am. Chem. Soc. 136 (2014), 17459–17467.
68. 68 Jarver, P., et al. In vivo biodistribution and efficacy of peptide mediated delivery. Trends Pharmacol. Sci. 31 (2010), 528–535.
69. 69 Pouny, Y., et al. Interaction of antimicrobial dermaseptin and its fluorescently labeled analogues with phospholipid membranes. Biochemistry 31 (1992), 12416–12423.
70. 70 Thennarasu, S., et al. Antimicrobial and membrane disrupting activities of a peptide derived from the human cathelicidin antimicrobial peptide LL37. Biophys. J. 98 (2010), 248–257.
71. 71 Alves, I.D., et al. Membrane interaction and perturbation mechanisms induced by two cationic cell penetrating peptides with distinct charge distribution. Biochim. Biophys. Acta 1780 (2008), 948–959.
72. 72 Cardoso, A.M., et al. S4(13)-PV cell-penetrating peptide induces physical and morphological changes in membrane-mimetic lipid systems and cell membranes: implications for cell internalization. Biochim. Biophys. Acta 1818 (2012), 877–888.
73. 73 Richard, J.P., et al. Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem. 278 (2003), 585–590.
74. 74 Maiolo, J.R., et al. Effects of cargo molecules on the cellular uptake of arginine-rich cell-penetrating peptides. Biochim. Biophys. Acta 1712 (2005), 161–172.
75. 75 van den Berg, A., Dowdy, S.F., Protein transduction domain delivery of therapeutic macromolecules. Curr. Opin. Biotechnol. 22 (2011), 888–893.
76. 76 Hitz, T., et al. Interaction of alpha-and beta-oligoarginine-acids and amides with anionic lipid vesicles: a mechanistic and thermodynamic study. Biochemistry 45 (2006), 5817–5829.
77. 77 van Asbeck, A.H., et al. Molecular parameters of siRNA–cell penetrating peptide nanocomplexes for efficient cellular delivery. ACS Nano 7 (2013), 3797–3807.
78. 78 Veiman, K.L., et al. PepFect14 peptide vector for efficient gene delivery in cell cultures. Mol. Pharm. 10 (2013), 199–210.
79. 79 Andaloussi, S.E., et al. Design of a peptide-based vector, PepFect6, for efficient delivery of siRNA in cell culture and systemically in vivo. Nucleic Acids Res. 39 (2011), 3972–3987.
80. 80 El-Sayed, A., et al. Delivery of macromolecules using arginine-rich cell-penetrating peptides: ways to overcome endosomal entrapment. AAPS J. 11 (2009), 13–22.
81. 81 Lundberg, P., et al. Delivery of short interfering RNA using endosomolytic cell-penetrating peptides. FASEB J. 21 (2007), 2664–2671.
82. 82 Sugita, T., et al. Improved cytosolic translocation and tumor-killing activity of Tat–shepherdin conjugates mediated by co-treatment with Tat-fused endosome-disruptive HA2 peptide. Biochem. Biophys. Res. Commun. 363 (2007), 1027–1032.
83. 83 Sirsi, S.R., et al. Functionalized PEG–PEI copolymers complexed to exon-skipping oligonucleotides improve dystrophin expression in mdx mice. Hum. Gene Ther. 19 (2008), 795–806.
84. 84 Wadia, J.S., et al. Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat. Med. 10 (2004), 310–315.
85. 85 Lo, S.L., Wang, S., An endosomolytic Tat peptide produced by incorporation of histidine and cysteine residues as a nonviral vector for DNA transfection. Biomaterials 29 (2008), 2408–2414.
86. 86 Mae, M., et al. A stearylated CPP for delivery of splice correcting oligonucleotides using a non-covalent co-incubation strategy. J. Control. Release 134 (2009), 221–227.
87. 87 Lindberg, S., et al. PepFect15, a novel endosomolytic cell-penetrating peptide for oligonucleotide delivery via scavenger receptors. Int. J. Pharm. 441 (2013), 242–247.
88. 88 Lawrence, M.S., et al. Overexpression of Bcl-2 with herpes simplex virus vectors protects CNS neurons against neurological insults in vitro and in vivo. J. Neurosci. 16 (1996), 486–496.
89. 89 Parsadanian, A.S., Bcl-xL is an antiapoptotic regulator for postnatal CNS neurons. J. Neurosci. 18 (1998), 1009–1019.
90. 90 Wiessner, C., et al. Neuron-specific transgene expression of Bcl-XL but not Bcl-2 genes reduced lesion size after permanent middle cerebral artery occlusion in mice. Neurosci. Lett. 268 (1999), 119–122.
91. 91 Asoh, S., et al. Protection against ischemic brain injury by protein therapeutics. Proc. Natl. Acad. Sci. U. S. A.​ 99 (2002), 17107–17112.
92. 92 Borsello, T., et al. A peptide inhibitor of c-Jun N-terminal kinase protects against excitotoxicity and cerebral ischemia. Nat. Med. 9 (2003), 1180–1186.
93. 93 Chen, L., et al. Opposing cardioprotective actions and parallel hypertrophic effects of delta PKC and epsilon PKC. Proc. Natl. Acad. Sci. U. S. A. 98 (2001), 11114–11119.
94. 94 Bright, R., et al. Protein kinase C delta mediates cerebral reperfusion injury in vivo. J. Neurosci. 24 (2004), 6880–6888.
95. 95 Leviton, A., et al. Microbiologic and histologic characteristics of the extremely preterm infant's placenta predict white matter damage and later cerebral palsy. The ELGAN study. Pediatr. Res. 67 (2010), 95–101.
96. 96 Hagberg, H., et al. The role of inflammation in perinatal brain injury. Nat. Rev. Neurol. 11 (2015), 192–208.
97. 97 Messina, S., et al. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice. Exp. Neurol. 198 (2006), 234–241.
98. 98 Monici, M.C., et al. Activation of nuclear factor-κB in inflammatory myopathies and Duchenne muscular dystrophy. Neurology 60 (2003), 993–997.
99. 99 Yellon, D.M., Baxter, G.F., Protecting the ischaemic and reperfused myocardium in acute myocardial infarction: distant dream or near reality?. Heart 83 (2000), 381–387.
100. 100 Matés, J.M., Effects of antioxidant enzymes in the molecular control of reactive oxygen species toxicology. Toxicology 163 (2000), 83–104.
101. 101 Zhang, Y.E., et al. In vivo protein transduction: delivery of PEP-1–SOD1 fusion protein into myocardium efficiently protects against ischemic insult. Mol. Cells 27 (2009), 159–166.
102. 102 Huang, G.Q., et al. The combined transduction of copper, zinc-superoxide dismutase and catalase mediated by cell-penetrating peptide, PEP-1, to protect myocardium from ischemia–reperfusion injury. J. Transl. Med., 9, 2011, 73.
103. 103 Boisguerin, P., et al. Systemic delivery of BH4 anti-apoptotic peptide using CPPs prevents cardiac ischemia–reperfusion injuries in vivo. J. Control. Release 156 (2011), 146–153.
104. 104 Vousden, K.H., Lu, X., Live or let die: the cell's response to p53. Nat. Rev. Cancer 2 (2002), 594–604.
105. 105 Snyder, E.L., et al. Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol., 2, 2004, e36.
106. 106 Smith, N.F., et al. Pharmacogenetics of irinotecan metabolism and transport: an update. Toxicol. In Vitro 20 (2006), 163–175.
107. 107 Crombez, L., et al. Targeting cyclin B1 through peptide-based delivery of siRNA prevents tumour growth. Nucleic Acids Res. 37 (2009), 4559–4569.
108. 108 Eguchi, A., et al. Efficient siRNA delivery into primary cells by peptide transduction–dsRNA binding domain (PTD–DRBD) fusion protein. Nat. Biotechnol. 27 (2009), 567–571.
109. 109 Eguchi, A., Dowdy, S.F., Efficient siRNA delivery by novel PTD–DRBD fusion proteins. Cell Cycle 9 (2010), 424–425.
110. 110 Michiue, H., et al. Induction of in vivo synthetic lethal RNAi responses to treat glioblastoma. Cancer Biol. Ther. 8 (2009), 2306–2313.
111. 111 Touchard, E., et al. A peptide inhibitor of c-Jun N-terminal kinase for the treatment of endotoxin-induced uveitis. Invest. Ophthalmol. Vis. Sci. 51 (2010), 4683–4693.
112. 112 Omotehara, Y., et al. Protection against ischemic cochlear damage by intratympanic administration of AM-111. Otol. Neurotol. 32 (2011), 1422–1427.
113. 113 Suckfuell, M., et al. Efficacy and safety of AM-111 in the treatment of acute sensorineural hearing loss: a double-blind, randomized, placebo-controlled Phase II study. Otol. Neurotol. 35 (2014), 1317–1326.
114. 114 Rothbard, J.B., et al. Conjugation of arginine oligomers to cyclosporin A facilitates topical delivery and inhibition of inflammation. Nat. Med. 6 (2000), 1253–1257.
115. 115 Vivès, E., et al. Cell-penetrating and cell-targeting peptides in drug delivery. Biochim. Biophys. Acta 1786 (2008), 126–138.
116. 116 Glogau, R., et al. Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type A topical gel for the treatment of moderate-to-severe lateral canthal lines. J. Drugs Dermatol. 11 (2012), 38–45.
117. 117 Garcia-Murray, E., Safety and efficacy of RT002, an injectable botulinum toxin type A, for treating glabellar lines: results of a Phase 1/2, open-label, sequential dose-escalation study. Dermatol. Surg. 41:Suppl. 1 (2015), S47–S55.
118. 118 Aartsma-Rus, A., et al. Therapeutic antisense-induced exon skipping in cultured muscle cells from six different DMD patients. Hum. Mol. Genet. 12 (2003), 907–914.
119. 119 Lu, Q.L., et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat. Med. 9 (2003), 1009–1014.
120. 120 Abes, R., et al. Cell-penetrating-peptide-based delivery of oligonucleotides: an overview. Biochem. Soc. Trans. 35 (2007), 775–779.
121. 121 Jia, L., et al. Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination. Cancer Chemother. Pharmacol. 68 (2011), 513–524.
122. 122 Koppelhus, U., et al. Cell-dependent differential cellular uptake of PNA, peptides, and PNA–peptide conjugates. Antisense Nucleic Acid Drug Dev. 12 (2002), 51–63.
123. 123 Violini, S., et al. Evidence for a plasma membrane-mediated permeability barrier to Tat basic domain in well-differentiated epithelial cells: lack of correlation with heparan sulfate. Biochemistry 41 (2002), 12652–12661.
124. 124 Simon, M.J., et al. TAT is not capable of transcellular delivery across an intact endothelial monolayer in vitro. Ann. Biomed. Eng. 39 (2011), 394–401.
125. 125 Lindgren, M.E., et al. Passage of cell-penetrating peptides across a human epithelial cell layer in vitro. Biochem. J. 377 (2004), 69–76.
126. 126 Foerg, C., et al. Differentiation restricted endocytosis of cell penetrating peptides in MDCK cells corresponds with activities of Rho-GTPases. Pharm. Res. 24 (2007), 628–642.
127. 127 Svensen, N., et al. Peptides for cell-selective drug delivery. Trends Pharmacol. Sci. 33 (2012), 186–192.
128. 128 Reissmann, S., Cell penetration: scope and limitations by the application of cell-penetrating peptides. J. Pept. Sci. 20 (2014), 760–784.
129. 129 Aguilera, T.A., et al. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr. Biol. (Camb.) 1 (2009), 371–381.
130. 130 Olson, E.S., et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr. Biol. (Camb.) 1 (2009), 382–393.
131. 131 Varkouhi, A.K., et al. Endosomal escape pathways for delivery of biologicals. J. Control. Release 151 (2011), 220–228.